NCT06152822View on ClinicalTrials.gov

Pyrotinib Combined With Capecitabine and Bevacizumab for Patients With HER2 Positive Breast Cancer and Brain Metastases

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 30, 2023

Primary Completion Date

November 30, 2024

Study Completion Date

November 30, 2025

Conditions
Breast Cancer With Brain Metastases
Interventions
DRUG

pyrotinib+capecitabine+bevacizumab

pyrotinib: ≥160mg qd capecitabine: 1000mg/m2,bid,q1-14,q3w bevacizumab:7.5mg/kg,iv,q3w

Trial Locations (1)

430000

RECRUITING

Tongji Hospital Affiliated of Tongji Medical College Huazhong University of Science and Technology, Wuhan

All Listed Sponsors
lead

Tongji Hospital

OTHER